About
Tomi is currently Chief Drug Hunter and President, Maestro Therapeutics, a consulting/advisory enterprise that is engaging academia, biotech and pharma to support peptide drug discovery. He retired from Merck Research Laboratories as Distinguished Scientist, Global Chemistry, where he provided leadership to the Peptide Drug Hunter Network and several peptide R&D programs as well as innovative core capabilities and knowledge engine. Tomi is an entrepreneurial drug hunter with four decades of industrial experience in both pharma and biotech. He is well known for his contributions to GPCR, kinase, protease and protein-protein interaction drug discovery. Tomi has two marketed drugs, including Scenesse® (a peptide superagonist of MCR1 for the treatment of the orphan skin disease known as erythropoietic protophyria and related indications) and Iclusig® (a small-molecule inhibitor of Bcr-Abl kinase for the treatment of resistant forms of chronic myelogenous leukemia). Other examples of his drug development campaigns include the peptidomimetic renin inhibitor Ditekiren, a natural product macrocycle mTOR antagonist Ridaforolimus and the first stapled peptide dual MDM2–MDMX antagonist ALRN-6924 to enter the clinic. Tomi is credited with >640 scientific publications, patents, and presentations and holds several Adjunct Professorships at the University of Massachusetts, the University of Massachusetts Medical School and Northeastern University Center for Drug Discovery. He is a Distinguished Alumni Scholar from his undergraduate alma mater, Minnesota State University at Moorhead, and served as a member of the MSUM Alumni Foundation Board of Directors. At his graduate alma mater, the University of Arizona, Tomi is a Distinguished Alumni Entrepreneur and has received a Professional Achievement Award from the Department of Chemistry & Biochemistry and the College of Science. In 2023, he will be launching a Peptide Drug Hunter Consortium and the Saint Albert the Great Institute for Science, Faith & Wisdom.
Activity
-
This is a significant step for us as we begin to develop cures for pediatric cancers and other rare diseases! I am very proud of our team.
This is a significant step for us as we begin to develop cures for pediatric cancers and other rare diseases! I am very proud of our team.
Liked by Tomi Sawyer
Experience
Education
Honors & Awards
-
University of Arizona Professional Achievement Award
University of Arizona Alumni Association & College of Science
-
Minnesota State University–Moorhead Class of 2008 Commencement Address
Minnesota State University–Moorhead
-
Minnesota State University–Moorhead Distinguished Alumni Award
Minnesota State University–Moorhead Alumni Foundation
-
Greenbush Middle River High School Class of 2004 Commencement Address
Greenbush Middle River High School
-
Milestone Award for Signal Transduction Drug Discovery Achievement
ARIAD Pharmaceuticals
-
President’s Distinguished Scientist Honorary Lecture in Pharmaceutical Research
Parke-Davis/Warner-Lambert Company (now Pfizer)
-
Kagan Drug Discovery Award for Lead Finding in Pharmaceutical Research
The Upjohn Company (now Pfizer)
-
DuVigneaud Award for Outstanding Achievement in Peptide Research
American Peptide Society
-
Minnesota State University–Moorhead Outstanding Young Alumni Award
Minnesota State University–Moorhead Alumni Foundation
-
University of Arizona Marvel Chemistry Honorarium
University of Arizona
More activity by Tomi
-
Attending Asia DDF Summit (Drug Delivery & Formulation) on 18-19th November? Be sure to check the panel on "Unlocking The Clinical Potential of RNA…
Attending Asia DDF Summit (Drug Delivery & Formulation) on 18-19th November? Be sure to check the panel on "Unlocking The Clinical Potential of RNA…
Liked by Tomi Sawyer
-
Time to submit those abstracts for APS/IPS 2025. If you want to be considered for an oral presentation, get them in before January 31st, 2025…
Time to submit those abstracts for APS/IPS 2025. If you want to be considered for an oral presentation, get them in before January 31st, 2025…
Liked by Tomi Sawyer
-
I'm delighted that Aileron and Advancium are evaluating ALRN-6924 as a potential treatment for a rare but devastating pediatric eye cancer. ALRN-6924…
I'm delighted that Aileron and Advancium are evaluating ALRN-6924 as a potential treatment for a rare but devastating pediatric eye cancer. ALRN-6924…
Liked by Tomi Sawyer
-
Great fun at the "40 under 40" party yesterday. Every year, the Boston Business Journal highlights the best young professionals in the Boston area…
Great fun at the "40 under 40" party yesterday. Every year, the Boston Business Journal highlights the best young professionals in the Boston area…
Liked by Tomi Sawyer
-
This is a major milestone for our team - our first and only in class cyclin inhibitor is now in the clinic! We could not have done this without the…
This is a major milestone for our team - our first and only in class cyclin inhibitor is now in the clinic! We could not have done this without the…
Liked by Tomi Sawyer
-
We are pleased to announce our participation in a $12M investment in Aralez Bio, a biotech company transforming the manufacture of amino…
We are pleased to announce our participation in a $12M investment in Aralez Bio, a biotech company transforming the manufacture of amino…
Liked by Tomi Sawyer
-
Join us in raising awareness for psoriasis and its impact on the whole family. #WorldPsoriasisDay #IL17 #Peptides #DrugDiscovery #PsoriasisFamily…
Join us in raising awareness for psoriasis and its impact on the whole family. #WorldPsoriasisDay #IL17 #Peptides #DrugDiscovery #PsoriasisFamily…
Liked by Tomi Sawyer
-
why we are all here my kids have done this with me a couple of times
why we are all here my kids have done this with me a couple of times
Liked by Tomi Sawyer
-
Period. New Sentence. New chapter. Today we announced that Fog Pharmaceuticals will henceforth be known as *Parabilis Medicines*. This name…
Period. New Sentence. New chapter. Today we announced that Fog Pharmaceuticals will henceforth be known as *Parabilis Medicines*. This name…
Liked by Tomi Sawyer
-
We are thrilled to share that our company has rebranded from Fog Pharma to Parabilis Medicines! The new name embodies our aspirations and signifies…
We are thrilled to share that our company has rebranded from Fog Pharma to Parabilis Medicines! The new name embodies our aspirations and signifies…
Liked by Tomi Sawyer
-
The first public disclosure of our first-in-human assessment using the miniprotein radioconjugate, AKY-1189, that targets Nectin-4. Congratulations…
The first public disclosure of our first-in-human assessment using the miniprotein radioconjugate, AKY-1189, that targets Nectin-4. Congratulations…
Liked by Tomi Sawyer
-
I’m excited to share with you all this research article, providing rigorous evidence that the UMass iCons program works to produce better outcomes in…
I’m excited to share with you all this research article, providing rigorous evidence that the UMass iCons program works to produce better outcomes in…
Liked by Tomi Sawyer
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More